Bavarian Nordic to Host Full Year 2016 Results Con
Post# of 301275
COPENHAGEN, Denmark - March 9, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2016 annual report on Wednesday, March 15, 2017.
The management of Bavarian Nordic will host a conference call at 2:00 pm CET (9:00 am EDT) on the same day to present the full-year results followed by a Q&A session.
Dial-in numbers for the conference call are: Denmark: +45 32 71 16 60, UK: +44 (0) 20 3427 1911, USA: +1 646 254 3364. Participant code is 7659153.
A live and archived webcast of the call and relevant slides will be available at http://bit.ly/2mXK6tS .
Contacts Europe: Rolf Sass Sørensen, Vice President Investor Relations & Communications. Phone +45 61 77 47 43 U.S.: Seth Lewis, Vice President, Investor Relations & Communications. Phone: +1 978 341 5271
About Bavarian Nordic Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases, based on the Company's live virus vaccine platform. Through long-standing collaborations, including a collaboration with the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for infectious diseases, including the non-replicating smallpox vaccine, IMVAMUNE ® , which is stockpiled for emergency use by the United States and other governments. The vaccine is approved in the European Union (under the trade name IMVANEX ® ) and in Canada. Bavarian Nordic and its partner Janssen are developing an Ebola vaccine regimen, which has been fast-tracked, with the backing of worldwide health authorities, and a vaccine for the prevention and treatment of HPV. Additionally, in collaboration with the National Cancer Institute, Bavarian Nordic has developed a portfolio of active cancer immunotherapies, including PROSTVAC ® , which is currently in Phase 3 clinical development for the treatment of advanced prostate cancer. The company has partnered with Bristol-Myers Squibb for the potential commercialization of PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on Twitter @bavariannordic .
(0)
(0)